【Remote or Hybrid】Fractional Head of AI/ML (CXO-Track)
Contract · Posted 4MO AGO
【Remote or Hybrid】Fractional Head of AI/ML (CXO-Track)
■About Logomix
Logomix is a platform biotech company pioneering the next generation of cell therapies. By combining large-scale genome engineering, automation, and single-cell transcriptomics, we are building a scalable system for functional cell manufacturing and high-throughput biological discovery.
Our current initiative focuses on optimizing the differentiation and function of iPSC-derived cell lineages. We're scaling up a single-gene knockout platform and leveraging AI/ML to extract meaningful insights from complex single-cell datasets — with future applications across multiple therapeutic cell types.
■The Opportunity
We’re seeking a fractional executive-level AI/ML leader to architect and implement our machine learning strategy from the ground up. This role will be a foundational contributor to our technical direction and data strategy, with potential to evolve into a full-time CXO role as the platform grows.
You’ll partner closely with our biology, bioinformatics, and executive teams to:
・Shape and lead the AI/ML roadmap aligned with experimental and business milestones
・Guide selection and implementation of key models (e.g., scGPT, GeneFormer, MOFA, or novel transformer architectures)
・Integrate experimental workflows (CRISPR knockouts, differentiation, scRNA-seq) with ML pipelines
・Explore scaling laws and predictive models for cell maturation, identity, and function
・Contribute to strategic decisions on platform development, team building, and partnerships
・Provide technical mentorship and help recruit future AI/ML team members
■Track
CXO-level growth opportunity
■About Logomix
Logomix is a platform biotech company pioneering the next generation of cell therapies. By combining large-scale genome engineering, automation, and single-cell transcriptomics, we are building a scalable system for functional cell manufacturing and high-throughput biological discovery.
Our current initiative focuses on optimizing the differentiation and function of iPSC-derived cell lineages. We're scaling up a single-gene knockout platform and leveraging AI/ML to extract meaningful insights from complex single-cell datasets — with future applications across multiple therapeutic cell types.
■The Opportunity
We’re seeking a fractional executive-level AI/ML leader to architect and implement our machine learning strategy from the ground up. This role will be a foundational contributor to our technical direction and data strategy, with potential to evolve into a full-time CXO role as the platform grows.
You’ll partner closely with our biology, bioinformatics, and executive teams to:
・Shape and lead the AI/ML roadmap aligned with experimental and business milestones
・Guide selection and implementation of key models (e.g., scGPT, GeneFormer, MOFA, or novel transformer architectures)
・Integrate experimental workflows (CRISPR knockouts, differentiation, scRNA-seq) with ML pipelines
・Explore scaling laws and predictive models for cell maturation, identity, and function
・Contribute to strategic decisions on platform development, team building, and partnerships
・Provide technical mentorship and help recruit future AI/ML team members
■Track
CXO-level growth opportunity
・Hands-on experience with single-cell multi-omic datasets (e.g., scRNA-seq, ATAC-seq, CITE-seq)
・Strong interest in induced pluripotent stem cell (iPSC) biology and regenerative medicine
・Shape the core AI strategy of a high-potential, next-gen cell therapy platform
・Start as a fractional contributor, grow into full-time CXO-level leadership
・Collaborate with a top-tier team across bioengineering, AI, and startup operations
・Work at the frontier of synthetic biology and data-driven discovery
■Publications
・Engineered yeast breaks new record: a genome with over 50% synthetic DNA
https://www.nature.com/articles/d41586-023-03495-4
・https://www.nikkei.com/article/DGXZQOUC0226S0S3A101C2000000/
・UKiS (Universal Knock-in System) Nature Comm. 13, 4219, 2022
https://www.titech.ac.jp/news/2022/064683
・APLoD (Assembling production of long DNAs) Molecular Cell 83, 4424–4437
仕事概要
Help Build the Future of AI-Driven Cell Therapy■About Logomix
Logomix is a platform biotech company pioneering the next generation of cell therapies. By combining large-scale genome engineering, automation, and single-cell transcriptomics, we are building a scalable system for functional cell manufacturing and high-throughput biological discovery.
Our current initiative focuses on optimizing the differentiation and function of iPSC-derived cell lineages. We're scaling up a single-gene knockout platform and leveraging AI/ML to extract meaningful insights from complex single-cell datasets — with future applications across multiple therapeutic cell types.
■The Opportunity
We’re seeking a fractional executive-level AI/ML leader to architect and implement our machine learning strategy from the ground up. This role will be a foundational contributor to our technical direction and data strategy, with potential to evolve into a full-time CXO role as the platform grows.
You’ll partner closely with our biology, bioinformatics, and executive teams to:
・Shape and lead the AI/ML roadmap aligned with experimental and business milestones
・Guide selection and implementation of key models (e.g., scGPT, GeneFormer, MOFA, or novel transformer architectures)
・Integrate experimental workflows (CRISPR knockouts, differentiation, scRNA-seq) with ML pipelines
・Explore scaling laws and predictive models for cell maturation, identity, and function
・Contribute to strategic decisions on platform development, team building, and partnerships
・Provide technical mentorship and help recruit future AI/ML team members
■Track
CXO-level growth opportunity
必須スキル
Help Build the Future of AI-Driven Cell Therapy■About Logomix
Logomix is a platform biotech company pioneering the next generation of cell therapies. By combining large-scale genome engineering, automation, and single-cell transcriptomics, we are building a scalable system for functional cell manufacturing and high-throughput biological discovery.
Our current initiative focuses on optimizing the differentiation and function of iPSC-derived cell lineages. We're scaling up a single-gene knockout platform and leveraging AI/ML to extract meaningful insights from complex single-cell datasets — with future applications across multiple therapeutic cell types.
■The Opportunity
We’re seeking a fractional executive-level AI/ML leader to architect and implement our machine learning strategy from the ground up. This role will be a foundational contributor to our technical direction and data strategy, with potential to evolve into a full-time CXO role as the platform grows.
You’ll partner closely with our biology, bioinformatics, and executive teams to:
・Shape and lead the AI/ML roadmap aligned with experimental and business milestones
・Guide selection and implementation of key models (e.g., scGPT, GeneFormer, MOFA, or novel transformer architectures)
・Integrate experimental workflows (CRISPR knockouts, differentiation, scRNA-seq) with ML pipelines
・Explore scaling laws and predictive models for cell maturation, identity, and function
・Contribute to strategic decisions on platform development, team building, and partnerships
・Provide technical mentorship and help recruit future AI/ML team members
■Track
CXO-level growth opportunity
歓迎スキル
■Preferred Qualifications・Hands-on experience with single-cell multi-omic datasets (e.g., scRNA-seq, ATAC-seq, CITE-seq)
・Strong interest in induced pluripotent stem cell (iPSC) biology and regenerative medicine
求める人物像
■Why Join Logomix?・Shape the core AI strategy of a high-potential, next-gen cell therapy platform
・Start as a fractional contributor, grow into full-time CXO-level leadership
・Collaborate with a top-tier team across bioengineering, AI, and startup operations
・Work at the frontier of synthetic biology and data-driven discovery
■Publications
・Engineered yeast breaks new record: a genome with over 50% synthetic DNA
https://www.nature.com/articles/d41586-023-03495-4
・https://www.nikkei.com/article/DGXZQOUC0226S0S3A101C2000000/
・UKiS (Universal Knock-in System) Nature Comm. 13, 4219, 2022
https://www.titech.ac.jp/news/2022/064683
・APLoD (Assembling production of long DNAs) Molecular Cell 83, 4424–4437
